14844 Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–IP–24–017, Collaborative Research 

on Influenza and Other Respiratory 

Pathogens in South Africa; and RFA–IP– 

24–081, Public Health Epidemiology, 

Prevention and Control of Influenza and 

Other Respiratory Pathogens in China. 

Date: May 17, 2024. 

Time: 10 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop H24–6, Atlanta, 

Georgia 30329–4027. Telephone: (404) 

718–8833; Email: GAnderson@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04198 Filed 2–28–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

In accordance with 5 U.S.C. 1009(d), 

the Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. 

Name of Committee: Safety and 

Occupational Health Study Section 

(SOHSS), National Institute for 

Occupational Safety and Health 

(NIOSH). 

Dates: June 4–5, 2024. 

Times: 11 a.m.–5 p.m., EDT. 

Place: Teleconference. 

Agenda: The meeting will convene to 

address matters related to the conduct of 

Study Section business and for the 

Study Section to consider safety and 

occupational health-related grant 

applications. 

For Further Information Contact: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, Office of Extramural 

Programs, National Institute for 

Occupational Safety and Health, Centers 

for Disease Control and Prevention, 

1095 Willowdale Road, Morgantown, 

West Virginia 26506. Telephone: (304) 

285–5951; Email: MGoldcamp@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04200 Filed 2–28–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the CDC/HRSA Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) and the Health 

Resources and Services Administration 

(HRSA) announce the following meeting 

of the CDC/HRSA Advisory Committee 

on HIV, Viral Hepatitis and STD 

Prevention and Treatment (CHAC). This 

meeting is open to the public, limited 

only by the number of audio and web 

conference lines (1,000 lines are 

available). Time will be available for 

public comment (registration is required 

to provide oral comment). 

DATES: The meeting will be held on 

April 9 and 10, 2024, from 9 a.m. to 4:30 

p.m., EDT. 

Written comments must be submitted 

by April 19, 2024. Registration to make 

oral comments must be submitted by 

March 26, 2024. 

ADDRESSES: The telephone access 

number is 1–669–254–5252, Webinar 

ID: 160 972 1316, and the Passcode is 

08044152. The web conference access is 

https://cdc.zoomgov.com/j/1609721316?

pwd=cUVqdUp5dlBNaDhhWER

rcWdXUk9yUT09, and the Passcode is 

dx%cJGp3. The number of available 

audio and web conference lines is 1,000. 

FOR FURTHER INFORMATION CONTACT: 

Marah Condit, M.S., Committee 

Management Lead, Office of Policy, 

Planning, and Partnerships, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop US8–6, Atlanta, 

Georgia 30329–4027. Telephone: (404) 

639–3423; Email: nchhstppolicy@

cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The CDC/HRSA Advisory 

Committee on HIV, Viral Hepatitis and 

STD Prevention and Treatment (CHAC) 

is charged with advising the Secretary of 

Health and Human Services; the 

Director, Centers for Disease Control 

and Prevention (CDC); and the 

Administrator, Health Resources and 

Services Administration (HRSA), 

regarding objectives, strategies, policies, 

and priorities for HIV, viral hepatitis, 

and STD prevention and treatment 

efforts including (1) surveillance; (2) 

epidemiologic, behavioral, health 

services, and laboratory research; (3) 

identification of policy issues and 

opportunities related to prevention and 

treatment including but not limited to 

professional education, healthcare 

delivery, social determinants of health, 

research, and prevention and treatment 

services; (4) strategic issues influencing 

the ability of CDC and HRSA to fulfill 

their missions; (5) development and 

implementation of federal programs 

focused on prevention and treatment; 

and (6) provide support to the agencies 

in their response to emerging health 

needs. 

Matters to be Considered: The agenda 

will include discussions on (1) 

syndemic approach to testing, (2) using 

prescription data to support the HIV 

care continuum, (3) HIV and aging, (4) 

an update on DoxyPEP, (5) advancing 

diagnosis of hepatitis C virus infection, 

(6) an update from the Long-Acting 

Injectable Workgroup, (7) an update 

from the Community Partnerships 

Workgroup, (8) an update from the 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 41 / Thursday, February 29, 2024 / Notices 14845 

Workforce Workgroup, and (9) an 

update from the Presidential Advisory 

Council on HIV/AIDS. Agenda items are 

subject to change as priorities dictate. 

Public Participation 

Written Public Comment: Members of 

the public are welcome to submit 

written comments in advance of the 

meeting. Written comments must be 

submitted by emailing nchhstppolicy@

cdc.gov with subject line ‘‘Spring CHAC 

Public Comment Registration’’ by April 

19, 2024. 

Oral Public Comment: Individuals 

who would like to make an oral 

comment during the public comment 

period must register by emailing 

nchhstppolicy@cdc.gov with subject 

line ‘‘Spring CHAC Public Comment 

Registration’’ by March 26, 2024. The 

public comment period is on April 9, 

2024, at 3:45 p.m., EDT. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–04197 Filed 2–28–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Advisory Board on 

Radiation and Worker Health, 

Subcommittee for Procedure Reviews, 

National Institute for Occupational 

Safety and Health 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting for the Subcommittee 

on Procedures Reviews (SPR) of the 

Advisory Board on Radiation and 

Worker Health (ABRWH or the Advisory 

Board). This meeting is open to the 

public, but without a public comment 

period. The public is also welcomed to 

listen to the meeting by joining the 

audio conference (information below). 

The audio conference line has 150 ports 

for callers. 

DATES: The meeting will be held on 

March 14, 2024, from 11 a.m. to 4:30 

p.m., EDT. 

Written comments must be received 

on or before March 7, 2024. 

ADDRESSES: You may submit comments 

by mail to: Rashaun Roberts, National 

Institute for Occupational Safety and 

Health, Centers for Disease Control and 

Prevention, 1090 Tusculum Avenue, MS 

C–24, Cincinnati, Ohio 45226. 

Meeting Information: Audio 

Conference Call via FTS Conferencing. 

The USA toll-free dial-in number is 1– 

866–659–0537; the pass code is 

9933701. 

FOR FURTHER INFORMATION CONTACT: 

Rashaun Roberts, Ph.D., Designated 

Federal Officer, National Center for 

Occupational Safety and Health, Centers 

for Disease and Prevention, 1090 

Tusculum Avenue, Mailstop C–24, 

Cincinnati, Ohio 45226, Telephone: 

(513) 533–6800; Email: ocas@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The Advisory Board on 

Radiation and Worker Health (ABRWH 

or the Advisory Board) was established 

under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000 to advise the 

President on a variety of policy and 

technical functions required to 

implement and effectively manage the 

new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines that 

have been promulgated by the 

Department of Health and Human 

Services (HHS) as a final rule; advice on 

methods of dose reconstruction, which 

have also been promulgated by HHS as 

a final rule; advice on the scientific 

validity and quality of dose estimation 

and reconstruction efforts being 

performed for purposes of the 

compensation program; and advice on 

petitions to add classes of workers to the 

Special Exposure Cohort. In December 

2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, 

which subsequently delegated this 

authority to CDC. NIOSH implements 

this responsibility for CDC. 

The charter was issued on August 3, 

2001, renewed at appropriate intervals, 

and rechartered under Executive Order 

14109 on March 22, 2022, and will 

terminate on March 22, 2024. 

Purpose: The Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advise the Secretary on 

whether there is a class of employees at 

any Department of Energy facility who 

were exposed to radiation but for whom 

it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. The 

ABWRH Subcommittee on Procedure 

Reviews (SPR) is responsible for 

overseeing, tracking, and participating 

in the reviews of all procedures used in 

the dose reconstruction process by the 

NIOSH Division of Compensation 

Analysis and Support (DCAS) and its 

dose reconstruction contractor (Oak 

Ridge Associated Universities—ORAU). 

Matters to be Considered: The agenda 

will include discussions on the 

following: 1. Carry-over items from 

November 16, 2023, SPR Meeting, 

including a. DCAS–PER–040 

‘‘Mallinckrodt TBD Revisions,’’ b. Peeks 

Street review—NIOSH, and c. ANL–W 

TBD revision—review application of 

ORAUT–RPRT–0097. 2. Newly-issued 

SC&A reviews, including a. ORAUT– 

RPRT–0071 ‘‘External Dose Coworker 

Methodology,’’ b. ORAUT–RPRT–0084 

‘‘Two-Count Filter Method for 

Measurement of Thoron Progeny in 

Air,’’ c. DCAS–PER–047 ST4 ‘‘GJOO,’’ d. 

‘‘Amchitka Island template,’’ e. 

‘‘Albuquerque Operations Office 

template,’’ f. DCAS–PER–068 ‘‘Electro 

Metallurgical Co,’’ g. DCAS–PER–070 

‘‘Nuclear Metals Inc.,’’ h. DCAS–PER– 

072 ‘‘Seymour Specialty Wiring Co,’’ i. 

ORAUT–RPRT–0060 ‘‘Neutron Dose 

from Highly Enriched Uranium.’’; 3. 

PERs previously identified as not 

needing a review; 4. Preparation for 

April 2024 Full ABRWH Meeting: 

Review of technical guidance 

documents ready for full Board 

approval; 5. Newly-Issued Guidance and 

Supplemental Topics. Agenda items are 

subject to change as priorities dictate. 

For additional information, please 

contact Toll Free 1 (800) 232–4636. 

Meeting Information: Audio 

Conference Call via FTS Conferencing. 

The USA toll-free dial-in number is 1– 

866–659–0537; the pass code is 

9933701. 

Public Participation 

Written Public Comment: The public 

is welcome to submit written comments 


khammond on DSKJM1Z7X2PROD with NOTICES